CUENasdaqPharmaceutical PreparationsFiscal year ends December 31

Cue Biopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$16.08−0.63 (-3.77%)

Close on Oct 19, 2026

Market cap: $101.96M
P/E (TTM): –
Dividend yield: –

Cue Biopharma, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	27	22	49	52	64	75	44	21	64	15
Short-Term Investments	–	0	0	25	0	10	15	18	0	–
Cash & Short-Term Investments	27	22	49	76	64	85	59	39	64	15
Receivables	5.55	0.95	1.70	0.06	3.14	1.42	0.75	–	–	–
Prepaid Expenses & Other	1.31	0.81	0.96	0.84	0.95	1.24	0.86	1.35	1.26	–
Total Current Assets	37	25	51	77	68	88	61	41	65	–
Property, Plant & Equipment	0.24	0.47	0.80	1.50	2.11	2.11	1.85	2.78	1.69	–
Gross Property, Plant & Equipment	3.90	4.15	4.41	5.74	5.56	4.91	3.87	4.15	2.35	–
Accumulated Depreciation	-3.66	-3.68	-3.62	-4.24	-3.44	-2.81	-2.03	-1.37	-0.66	–
Operating Lease Right-of-Use Assets	4.07	4.37	6.32	9.20	9.81	6.77	5.34	–	–	–
Other Long-Term Assets	0.09	0.11	0.12	0.13	0.14	0.40	0.67	0.81	0.20	–
Total Assets	42	32	62	91	83	100	72	45	67	–
Accounts Payable	3.95	2.82	3.50	2.73	2.59	2.07	0.88	2.04	1.66	–
Accrued Expenses	1.61	2.91	4.14	3.55	4.62	2.79	2.23	1.79	1.15	–
Short-Term Debt	–	0.04	0.04	0.07	–	–	–	–	–	–
Current Portion of Long-Term Debt	–	–	4.00	2.00	–	–	–	–	–	–
Current Debt	–	0.04	4.04	2.07	–	–	–	–	–	–
Current Portion of Leases	1.91	3.54	3.37	3.30	4.93	4.78	4.45	–	–	–
Total Current Liabilities	13	14	17	12	13	16	12	6.22	5.35	–
Long-Term Debt	–	0	4.20	8.04	0	–	–	–	–	–
Long-Term Leases	2.29	1.00	3.16	6.02	5.12	2.37	1.35	–	–	–
Operating Lease Liabilities	4.20	4.54	0.01	9.32	10	7.15	5.80	–	–	–
Total Liabilities	16	15	24	26	18	21	17	11	5.35	–
Total Debt	–	0.04	8.24	10	0	–	–	–	–	–
Preferred Stock	0	0	0	0	0	0	–	–	–	–
Common Stock	0.00	0.06	0.05	0.04	0.03	0.03	0.03	0.02	0.02	–
Additional Paid-In Capital	395	359	338	316	263	232	163	106	94	–
Retained Earnings	-368	-342	-301	-250	-197	-153	-109	-72	-33	–
Comprehensive Income & Other	–	0	0	-0.10	0	0.01	-0.01	-0.01	–	–
Shareholders' Equity	26	17	37	66	65	79	55	34	62	15
Total Equity	26	17	37	66	65	79	55	34	62	15
Total Liabilities & Equity	42	32	62	91	83	100	72	45	67	–
Shares Outstanding(shares)	3.22	2.06	1.57	1.57	1.07	1.01	0.89	0.69	0.65	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -262.0%
Net margin: -435.8%
Return on equity, FY2025: -121.1%

Financial strength

Current ratio: 1.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 82.0%

Valuation

P/E ratio: –
Price to sales: 2.71
Price to book: 44.14
Dividend yield: –